Cargando…

Prospect of Prostate Cancer Treatment: Armed CAR-T or Combination Therapy

SIMPLE SUMMARY: There is still no effective treatment for advanced prostate cancer. CAR-T therapy is a promising approach; however, many obstacles remain for the treatment of solid tumors due to the complex physical barriers and inhibitory microenvironment in solid tumors. Single CAR-T therapy has a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Yao, Wen, Weihong, Yang, Fa, Han, Donghui, Zhang, Wuhe, Qin, Weijun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869943/ https://www.ncbi.nlm.nih.gov/pubmed/35205714 http://dx.doi.org/10.3390/cancers14040967

Ejemplares similares

Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies
por: Yang, Fa, et al.
Publicado: (2016)

High mobility group box 1 promotes the epithelial-to-mesenchymal transition in prostate cancer PC3 cells via the RAGE/NF-κB signaling pathway
por: Zhang, Jingliang, et al.
Publicado: (2018)

Integrated bioinformatics analysis of IFITM1 as a prognostic biomarker and investigation of its immunological role in prostate adenocarcinoma
por: Qiao, Shaoyi, et al.
Publicado: (2022)

A novel anti-PSMA human scFv has the potential to be used as a diagnostic tool in prostate cancer
por: Han, Donghui, et al.
Publicado: (2016)

Expression of Prostate-Specific Membrane Antigen in Tumor-Associated Vasculature Predicts Poor Prognosis in Hepatocellular Carcinoma
por: Jiao, Dian, et al.
Publicado: (2019)

Knockdown of RNF2 induces cell cycle arrest and apoptosis in prostate cancer cells through the upregulation of TXNIP
por: Wei, Ming, et al.
Publicado: (2016)

The higher levels of self-reported satisfaction, the lower risk of depressive symptoms: Evidence from a nationwide cross-sectional study in China
por: Niu, Zhiping, et al.
Publicado: (2022)

Establishment and prospective validation of an SUV(max) cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by (68)Ga-PSMA PET/CT: a real-world study
por: Jiao, Jianhua, et al.
Publicado: (2021)

The Diagnostic and Immunotherapeutic Value of CD248 in Renal Cell Carcinoma
por: Zhang, Keying, et al.
Publicado: (2021)

CAR-T cell combination therapy: the next revolution in cancer treatment
por: Al-Haideri, Maysoon, et al.
Publicado: (2022)

CD248 promotes migration and metastasis of osteosarcoma through ITGB1-mediated FAK-paxillin pathway activation
por: Lu, Shiqi, et al.
Publicado: (2023)

Prospects for combined use of oncolytic viruses and CAR T-cells
por: Ajina, Adam, et al.
Publicado: (2017)

Galectin-9 expression predicts poor prognosis in hepatitis B virus-associated hepatocellular carcinoma
por: Jiao, Jianhua, et al.
Publicado: (2022)

Single-cell analysis of multiple cancer types reveals differences in endothelial cells between tumors and normal tissues
por: Zhang, Jiayu, et al.
Publicado: (2022)

Emerging Novel Combined CAR-T Cell Therapies
por: Nguyen, Anh, et al.
Publicado: (2022)

Combination therapy: A feasibility strategy for CAR-T cell therapy in the treatment of solid tumors
por: Xu, Jinjing, et al.
Publicado: (2018)

Combining chemotherapy with CAR-T cell therapy in treating solid tumors
por: Wang, Arthur Xuan, et al.
Publicado: (2023)

Correction to: Endosialin‑positive tumor‑derived pericytes promote tumor progression through impeding the infiltration of CD8(+) T cells in clear cell renal cell carcinoma
por: Lu, Tong, et al.
Publicado: (2023)

Endosialin-positive tumor-derived pericytes promote tumor progression through impeding the infiltration of CD8(+) T cells in clear cell renal cell carcinoma
por: Lu, Tong, et al.
Publicado: (2023)

CAR‐T therapy: Prospects in targeting cancer stem cells
por: Cui, Xiaoyue, et al.
Publicado: (2021)

Prospective approaches to enhancing CAR T cell therapy for glioblastoma
por: Choi, Sun Il, et al.
Publicado: (2022)

Arming NK cells with enhanced antitumor activity: CARs and beyond
por: Oberoi, Pranav, et al.
Publicado: (2013)

Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells
por: Thakur, Archana, et al.
Publicado: (2021)

Efficacy and Safety of Silodosin and Dutasteride Combination Therapy in Acute Urinary Retention due to Benign Prostatic Hyperplasia: A Single-Arm Prospective Study
por: Hagiwara, Kazuhisa, et al.
Publicado: (2016)

Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells
por: Wang, Hongxia, et al.
Publicado: (2021)

Prognostic Value of Vascular-Expressed PSMA and CD248 in Urothelial Carcinoma of the Bladder
por: Li, Yu, et al.
Publicado: (2021)

Photodynamic therapy for prostate cancer: Recent advances, challenges and opportunities
por: Xue, Qin, et al.
Publicado: (2022)

Target selection for CAR-T therapy
por: Wei, Jianshu, et al.
Publicado: (2019)

Prognostic value and underlying mechanism of autophagy-related genes in bladder cancer
por: Peng, Shiyuan, et al.
Publicado: (2022)

CD248 as a bridge between angiogenesis and immunosuppression: a promising prognostic and therapeutic target for renal cell carcinoma
por: Liu, Shaojie, et al.
Publicado: (2021)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Recent Prospective in CAR T-Based Therapy for Solid and Hematological Malignancies
por: Marei, Hany E., et al.
Publicado: (2023)

New development in CAR-T cell therapy
por: Wang, Zhenguang, et al.
Publicado: (2017)

Insight into the Progress in CAR-T Cell Therapy and Combination with Other Therapies for Glioblastoma
por: Liang, Tingyu, et al.
Publicado: (2023)

Single-cell analysis reveals the COL11A1(+) fibroblasts are cancer-specific fibroblasts that promote tumor progression
por: Zhang, Jiayu, et al.
Publicado: (2023)

Seatbelts in CAR therapy: How Safe Are CARS?
por: Minagawa, Kentaro, et al.
Publicado: (2015)

Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1–2 trial
por: Zhang, Yajing, et al.
Publicado: (2021)

Development and optimization of PSCA-specific CAR T cells for the treatment of bone metastatic prostate cancer
por: Gerdts, Ethan, et al.
Publicado: (2015)

CAR-T Plus Radiotherapy: A Promising Combination for Immunosuppressive Tumors
por: Qin, Vicky Mengfei, et al.
Publicado: (2022)

CAR-T cell therapy: a potential new strategy against prostate cancer
por: Schepisi, Giuseppe, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gai82iv2dmr5eovflup2d0paik